Originators that make discounts on biologic list prices conditional on hospitals not switching treatment to anti-TNF biosimilars may be breaching competition law, the Netherlands’ competition authority is warning.

UK concession prices have a history of often failing to keep up with rising prices in the marketplace. However, the latest figures from WaveData suggest that even when prices are falling, concessions can sometimes struggle to compensate independent pharmacists at an adequate price level.

Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.

India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”

Immediately upon reimbursement listing, Mylan has launched in Australia the insulin glargine biosimilar that it co-developed with India’s Biocon. 

Grouping together biosimilar adalimumabs and etanercepts with patented biologics in the same reference-price group in Germany threatens to remove biosimilars’ market advantage and weaken competition, local industry fears.